SANUWAVE Well being, Inc. at the moment introduced the appointment of Dr. Toni Rinow as CFO
Eden Prairie, MN, Aug. 16, 2022 (GLOBE NEWSWIRE) — through NewMediaWire — SANUWAVE Well being, Inc. (OTCPK: SNWV), a number one supplier of next-generation wound care merchandise, at the moment introduced the appointment of Dr. Toni Rinow, MBA as Chief Monetary Officer (CFO).
“With SEC filings present and up to date financing finalized, bringing in a world-class CFO to construct out the accounting and finance perform is a strategic subsequent step for SANUWAVE,” acknowledged Kevin Richardson, SANUWAVE CEO. “Dr. Rinow involves us with a depth of expertise, together with a powerful historical past of driving enterprise transformations and income acceleration. We really feel she is going to add large worth to the SANUWAVE crew and are excited to take this subsequent step as we transfer the corporate ahead.”
Dr. Rinow is a transformational finance and enterprise chief with over 20 years of expertise and a confirmed observe file in worldwide company improvement. Toni makes a speciality of guiding firms via inflection factors of development, innovation, know-how convergence and enterprise integration. She is a catalyst for development and growth and is well-known for accelerating income streams via acquisitions, company improvement, gross sales and advertising, and financings. Toni transforms information into actionable methods and most just lately served in a NASDAQ-traded wellness firm elevating over $130 million in capital growth financing and executed on acquisitions securing a Morgan Stanley capital-backed portfolio.
Toni led healthcare organizations as Common Supervisor at world nuclear drugs chief Jubilant Draximage Inc and as Chief Working Officer at Isologic Revolutionary Radiopharmaceuticals. Her skilled profession contains management roles in each private and non-private pharmaceutical and healthcare organizations, the place she spearheaded acquisitions throughout Canada, Latin America, Europe, India and USA and supported the transition of biotechnology firms to an preliminary public providing. Toni has efficiently facilitated the negotiation of worldwide company alliances valued at over $100M and overseen a life science funding portfolio with $400M below administration.
Dr. Rinow holds an MBA and a Masters in Accounting from McGill College, in addition to a chemical engineer diploma from ERASMUS European Greater Institute of Chemistry in Strasbourg, France, and a Ph.D. in Biophysics and Chemistry from the College of Montreal. She is educated in synthetic intelligence at MIT Massachusetts Institute of Expertise. Dr. Rinow believes in giving again to the group and sat on the Board of Administrators in a number of non-for-profit organizations.
SANUWAVE Well being is concentrated on the analysis, improvement, and commercialization of its patented, non-invasive, and organic response-activating medical programs for the restore and regeneration of pores and skin, musculoskeletal tissue, and vascular buildings.
SANUWAVE’s ENERGY FIRST wound care portfolio options regenerative drugs merchandise and product candidates that assist restore the physique’s regular therapeutic processes. SANUWAVE applies and researches its patented vitality switch applied sciences in wound therapeutic, orthopedic/backbone, aesthetic/beauty, and cardiac/endovascular situations.
This press launch could comprise “forward-looking statements” throughout the which means of the Non-public Securities Litigation Reform Act of 1995, reminiscent of statements referring to monetary outcomes and plans for future enterprise improvement actions and are thus potential. Ahead-looking statements embody all statements that aren’t statements of historic reality relating to intent, perception or present expectations of the Firm, its administrators or its officers. Traders are cautioned that any such forward-looking statements will not be ensures of future efficiency and contain dangers and uncertainties, a lot of that are past the Firm’s capability to manage. Precise outcomes could differ materially from these projected within the forward-looking statements. Among the many key dangers, assumptions and components which will have an effect on working outcomes, efficiency and monetary situation are dangers related to the regulatory approval and advertising of the Firm’s product candidates and merchandise, unproven pre-clinical and medical improvement actions, regulatory oversight, the Firm’s capability to handle its capital useful resource points, competitors, and the opposite components mentioned intimately within the Firm’s periodic filings with the Securities and Trade Fee. The Firm undertakes no obligation to replace any forward-looking assertion.
Senior Director, Advertising & Program Administration